158 related articles for article (PubMed ID: 11723269)
1. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine.
Dahlöf C; Tfelt-Hansen P; Massiou H; Fazekas A;
Neurology; 2001 Nov; 57(10):1811-7. PubMed ID: 11723269
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study.
Cabarrocas X;
Clin Ther; 2001 Nov; 23(11):1867-75. PubMed ID: 11768838
[TBL] [Abstract][Full Text] [Related]
3. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine.
Mathew NT;
Headache; 2002 Jan; 42(1):32-40. PubMed ID: 12005273
[TBL] [Abstract][Full Text] [Related]
4. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial.
Dowson AJ; Massiou H; Laínez JM; Cabarrocas X
Cephalalgia; 2002 Jul; 22(6):453-61. PubMed ID: 12133045
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on almotriptan in migraine.
Keam SJ; Goa KL; Figgitt DP
CNS Drugs; 2002; 16(7):501-7. PubMed ID: 12056924
[TBL] [Abstract][Full Text] [Related]
6. Oral almotriptan in the treatment of migraine: safety and tolerability.
Dodick DW
Headache; 2001 May; 41(5):449-55. PubMed ID: 11380642
[TBL] [Abstract][Full Text] [Related]
7. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
8. Almotriptan: a review of its use in migraine.
Keam SJ; Goa KL; Figgitt DP
Drugs; 2002; 62(2):387-414. PubMed ID: 11817980
[TBL] [Abstract][Full Text] [Related]
9. Almotriptan improves response rates when treatment is within 1 hour of migraine onset.
Dowson AJ; Massiou H; Lainez JM; Cabarrocas X
Headache; 2004 Apr; 44(4):318-22. PubMed ID: 15109355
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial.
Linder SL; Mathew NT; Cady RK; Finlayson G; Ishkanian G; Lewis DW
Headache; 2008 Oct; 48(9):1326-36. PubMed ID: 18484981
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Diener HC
Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
[TBL] [Abstract][Full Text] [Related]
12. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
[TBL] [Abstract][Full Text] [Related]
13. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison.
Spierings EL; Gomez-Mancilla B; Grosz DE; Rowland CR; Whaley FS; Jirgens KJ
Arch Neurol; 2001 Jun; 58(6):944-50. PubMed ID: 11405809
[TBL] [Abstract][Full Text] [Related]
14. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study.
Pascual J; Falk RM; Piessens F; Prusinski A; Docekal P; Robert M; Ferrer P; Luria X; Segarra R; Zayas JM
Cephalalgia; 2000 Jul; 20(6):588-96. PubMed ID: 11075844
[TBL] [Abstract][Full Text] [Related]
15. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
Diener HC; Gendolla A; Gebert I; Beneke M
Headache; 2005; 45(7):874-82. PubMed ID: 15985104
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials.
Dahlöf CG; Pascual J; Dodick DW; Dowson AJ
Cephalalgia; 2006 Apr; 26(4):400-8. PubMed ID: 16556240
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and efficacy of almotriptan in the long-term treatment of migraine.
Pascual J; Falk R; Docekal R; Prusinski A; Jelencsik J; Cabarrocas X; Segarra X; Luria X; Ferrer P
Eur Neurol; 2001; 45(4):206-13. PubMed ID: 11385257
[TBL] [Abstract][Full Text] [Related]
18. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.
Goadsby PJ; Ferrari MD; Olesen J; Stovner LJ; Senard JM; Jackson NC; Poole PH
Neurology; 2000 Jan; 54(1):156-63. PubMed ID: 10636142
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of oral almotriptan: interim analysis of a 1-year open study.
Cabarrocas X; Esbri R; Peris F; Ferrer P
Headache; 2001 Jan; 41(1):57-62. PubMed ID: 11168604
[TBL] [Abstract][Full Text] [Related]
20. Early intervention with almotriptan improves sustained pain-free response in acute migraine.
Mathew NT
Headache; 2003; 43(10):1075-9. PubMed ID: 14629242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
